Treats central precocious puberty (CPP) (gonadotropin-dependent precocious puberty). Sold as Synarel. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Nafarelin Acetate (sold as Synarel), first approved Feb 13, 1990, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Synarel | Part D | $96K | -58% | 0 |
| GnRH for Luteal Support - Mechanism of ActionGnRH Antagonist IVF Protocol, Fresh Embryo Transfer · Heli Alexandroni | — | Recruiting | Jun 2, 2026 |
| Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus ProgesteroneIvf, Frozen Embryo Transfer (FET) · Shaare Zedek Medical Center | Early phase 1 | Not yet recruiting | Mar 11, 2025 |
| Intranasal Nafarelin For Triggering Oocyte MaturationFertility Preservation · Fundacion Dexeus | Phase 4 | Recruiting | Jan 8, 2025 |
| Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI CyclesIn Vitro Fertilization, ICSI Intracytoplasmic Spermatozoid Injection · Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Nov 29, 2023 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Pfizer